Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
Authors:
- Tiffini VossTVTiffini Voss
- Daun BahrDBDaun Bahr
- Jeffrey CummingsJCJeffrey Cummings
- Roger MillsRMRoger Mills
- Bernard RavinaBRBernard Ravina
- Hilde WilliamsHWHilde Williams
- 1 March 2013
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 19 (3) , 295-299
Abstract
No abstract availableKeywords
Funding Information
- ACADIA Pharmaceuticals (PIM-006, PIM-012, PIM-014)
- Orphan Drug Division of the Food and Drug Administration (FD-R-001416-02)
- Parkinson Study Group
This publication has 11 references indexed in Scilit:
- Performance of the scale for assessment of positive symptoms in Parkinson's disease psychosisMovement Disorders, 2010
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease PsychosisNeuropsychopharmacology, 2009
- The placebo treatments in neurosciencesNeurology, 2008
- Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationPLOS Medicine, 2008
- Scales to assess psychosis in Parkinson's disease: Critique and recommendationsMovement Disorders, 2008
- Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work groupMovement Disorders, 2007
- Longitudinal outcome of Parkinson’s disease patients with psychosisNeurology, 2003
- Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration DatabaseJournal of Clinical Psychopharmacology, 2002
- Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factorsBrain, 2000
- Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's DiseaseNew England Journal of Medicine, 1999